Cenes Pharma - 500 Beiträge pro Seite

[BrauchGeld]

Hi

Eine Chance noch günstig einzusteigen.

Cenes Pharma
Marktcap: ca.50 mio€

www.cenes

Pipeline:

CeNeS is committed to the development of novel, improved drugs against clinically validated targets of the central nervous system. The focus on well validated targets means that its development programmes have a lower risk profile and the potential to progress rapidly to clinical proof of concept.

Post-operative pain

Morphine formulations are currently the treatment of choice in the control of severe pain. An active potent metabolite of morphine, morphine-6-glucuronide may have clinical advantages over morphine based on studies in man showing that M6G, in addition to having an equivalent analgesic effect, may have a reduced tendency to cause respiratory depression, nausea and vomiting.



CeNeS owns patents claiming novel synthetic routes for the manufacture of M6G. CeNeS announced in January 2000 that it had acquired from Nycomed Amersham patents covering innovative and cost effective routes of synthesis for M6G, plus human safety and tolerance data and the results of human clinical trials using M6G in more than 400 patients suffering post-operative pain. These additional data have helped CeNeS design studies to show the efficacy and side effect profile of M6G compared to morphine.



Phase II clinical trials have shown that M6G produces equivalent analgesia to morphine to combat post-operative pain. Additional clinical studies in post-operative nausea and vomiting have also shown that M6G reduced the incidence of nausea and vomiting when compared directly with morphine. These data have confirmed that M6G induces equivalent analgesia to morphine combined with an improved side effect profile. In particular, M6G appears to cause a significantly lower frequency and severity of nausea and vomiting than morphine. If CeNeS is able to confirm in larger phase III clinical trials that M6G causes fewer side effects than morphine but has equal analgesic efficacy, then this could produce an attractive alternative for patients and healthcare providers.



M6G completed an initial Phase III trial in mid-2004. The trial recruited 167 patients in hospitals in three European countries, suffering from post-operative pain following knee surgery carried out under spinal anaesthesia. The prime objective of the study was to compare the analgesic efficacy and duration of action of a range of doses of M6G given intravenously, compared with placebo. On 20th September 2004 CeNeS announced the successful preliminary results of this Phase III trial (see Press Release). A second Phase III trial is planned to commence in early 2005 and it is expected that an initial European product filing could be made in 2006.

Neuropathic pain
A range of primary diseases or conditions including cancer, diabetes, HIV/AIDS and shingles can result in nerve damage and subsequent chronic pain. This neuropathic pain is difficult to treat as traditional analgesics do not provide adequate relief for many patients. Drug treatments for neuropathic pain represent a significant area of unmet medical need and a growing market opportunity. Glutamate (particularly NMDA) receptors have been implicated in the induction and maintenance of neuropathic pain in animal models, and NMDA antagonists have been shown to be effective in animal models of persistent pain.



CNS 5161 is a blocker of the NMDA ion channel and is currently in Phase II proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.



Two Phase I studies using CNS 5161 have already been completed. Both studies were conducted in male volunteers. The first demonstrated the safety and tolerability of selected doses of CNS 5161 given intravenously. Data from the first study were used to choose potentially effective doses that produced little in the way of side effects in the volunteers. The second study examined the reduction in pain experienced after placebo, morphine and two separate doses of CNS 5161 (0.25mg and 0.5mg), administered on separate occasions to sixteen male volunteers. CNS 5161 at 0.5mg was found to produce a statistically significant reduction in perceived pain as compared to either morphine or placebo.



An initial phase IIa study has been completed in 10 patients with chronic neuropathic pain. This study demonstrated that 0.25mg of CNS 5161 gave statistically significant pain relief following intravenous infusion of the drug over six hours. The drug was well tolerated by the patients. CeNeS is currently undertaking an extended Phase II trial of CNS 5161, from which results are expected in H1 - 2005.

Short acting sedative
With the growing trend towards day case hospital procedures, sedative agents that permit rapid recovery and hence rapid discharge from hospital are in increasing demand. Benzodiazepines acting at the GABA receptor are widely used to reduce anxiety and provide sedation. However, the therapeutic effects of existing agents (e.g. midazolam) are often confounded by over-sedation and prolongation of effects, the latter being caused by active metabolites and drug-drug interactions. CeNeS has acquired from GlaxoSmithKline a series of water-soluble, rapid and short-acting GABA receptor modulators interacting with the benzodiazepine site. The lead compound CNS 7056X is now in pre-clinical development. Data generated to date show that this agent has a fast onset of action and a short duration of action. Unlike midazolam, it has no known active metabolites and its elimination is organ-independent, minimising the potential for drug-drug interactions and potentially allowing its use in patients with compromised organ function.

Parkinson`s disease
Parkinson`s disease is the second most common neurodegenerative disease after Alzheimer`s disease. It affects approximately 2% of the population over the age of 65. The symptoms of Parkinson`s disease such as tremor, rigidity and slowness of movement result from the loss of neurones containing the neurotransmitter dopamine in parts of the brain responsible for controlling movement. Replacement therapy using the precursor of dopamine, L-DOPA combined with a dopa-decarboxylase inhibitor (carbidopa or benserazide) is the mainstay of therapy in Parkinson’s disease. Catechol-O-methyltransferase (COMT) is a key enzyme that metabolises catecholamines such as L-DOPA and causes a significant depletion of L-DOPA in the brain and periphery, limiting its efficacy. COMT inhibitors smooth out the pharmacokinetics of L-DOPA, giving patients a longer ‘on’ or functional time each day. However, existing COMT inhibitors have significant problems including liver toxicity (tolcapone), poor brain penetration (entacapone) and poor oral bioavailability (entacapone). The problems associated with the current generation of COMT inhibitors are thought to result from the chemical class to which they belong i.e. nitrocatechols. CeNeS has novel series of COMT inhibitors which are not nitrocatechols and which have the potential to provide a significantly superior profile compared with current agents. This programme is in the lead optimisation phase.

Other assets
CeNeS is considering the development of M6G for chronic pain, and is undertaking certain preliminary studies for this indication. CeNeS also has rights to a novel dopamine D1 receptor antagonist, CEE 03-320, which is ready to enter Phase I clinical trials and is indicated for substance abuse and sleep disorders. In addition CeNeS has a novel series of neuromuscular blocking compounds. The neuromuscular blocker programme is focused on identifying new, short acting agents for use in surgical procedures.

21.01.2005 :

CeNeS Pharmaceuticals PLC
21 January 2005


CeNeS announces Confirmation of Positive M6G Phase III Clinical Trial Results
and an Update on the Final European Phase III trial in Post-Operative pain

Cambridge, UK, 21st January 2005 - CeNeS Pharmaceuticals plc (LSE: CEN) (`CeNeS`
or `the Company`) today announced that further to the preliminary results
released on September 20th 2004 CeNeS now has the final audited results from a
European Phase III trial to assess the efficacy of M6G (morphine-6-glucuronide)
as an analgesic in patients suffering from post-operative pain. CeNeS is now
completing its plans for a final European Phase III trial. The trial is
anticipated to commence in the second quarter of 2005. If this trial is also
successful CeNeS expects that it will be able to make a European product filing
in 2006 prior to a product launch in 2007.


Results of first Phase III trial

The analysis of the Phase III results from a trial of 168 patients has confirmed
that M6G is an effective analgesic agent for the treatment of post-operative
pain following knee replacement surgery under spinal nerve block. A single,
intravenous administration of M6G (30mg/70kg) showed a statistically significant
(p<0.05) reduction of morphine consumption by patient controlled analgesia
(`PCA`) at 12 and 24 hours after administration. The study also showed a clear
dose response relationship, with a decrease in the amount of morphine consumed
as the dose of M6G increased. The dose linear trend was statistically
significant (p<0.05). The observation that M6G (30mg/70kg) is effective for up
to 24 hours indicates that M6G provides long lasting analgesia. The study
results also showed that M6G is safe and well tolerated.

The trends in secondary outcome measures such as nausea and vomiting indicate
that the incidence of nausea and vomiting over early time periods after test
drug administration was low and M6G groups were similar to placebo, indicating
that M6G does not appear to induce nausea or vomiting. This supports the clear
trend in an earlier Phase II study in post-operative pain that showed that M6G
induced less nausea and vomiting than morphine at equianalgesic doses. As
expected when the study was designed, the use of morphine PCA by all patients in
the trial prevents further detailed analysis of the benefits of M6G in reducing
nausea and vomiting. This will be examined in greater detail in the second Phase
III trial outlined later in this release.

Dr. A. Binning, Principal Investigator on the recent Phase III study and
Consultant in Anaesthesia & Intensive Care at the Western & Gartnavel Hospital
in Glasgow commented,

`There is an acknowledged demand for a new pain drug for the treatment of
post-operative pain. For any new drug to displace current treatments such as
morphine and/or other opiates in this setting it needs to be equipotent to
morphine as an analgesic but with a better side effect profile. My experience of
using M6G in the latest Phase III and an earlier Phase II study confirms the
potential of M6G to meet this demanding profile.`


Status Update on Final European Phase III trial

The analysis of the first set of Phase III data and the experience CeNeS has
gained from successfully completing a Phase III trial in post-operative pain has
been important in designing the final Phase III trial. CeNeS is now putting in
place a protocol structured to meet the requirements of the regulatory
authorities in Europe to demonstrate the planned clinical benefits of M6G
namely:-

•Effective analgesic for up to 48 hours when administered by loading dose
and PCA for the treatment of moderate to severe post-operative pain
•Reduced opiate induced nausea and vomiting
•Efficacy in a broad range of surgical procedures

Data from other academic sources also suggests that M6G has a beneficial
pharmokinetic profile and causes less respiratory depression when compared to
the `gold standard` morphine treatment.

The final Phase III study is designed to compare directly M6G and morphine in
post-operative pain. The study will be carried out following, primarily, open
abdominal surgery under general anaesthesia and is designed and powered to
investigate both non-inferiority of analgesic effects and superiority of side
effect profiles, particularly nausea, between the M6G and morphine arms. The
study will be a pivotal multi-centre, two arm comparator study in approximately
400 patients to demonstrate statistically both equipotency of M6G and morphine
administered by PCA following bolus dosing.

Neil Clark, Chief Executive said `The global market for post-operative pain
relief was valued at approximately $1 billion in 2000, and is estimated to be
growing at 6-7% per annum. There is a significant opportunity for CeNeS in
realising the clinical and commercial potential of M6G as an effective analgesic
with a good side effect profile. CeNeS has sufficient funds to deliver the
second Phase III in Europe and is well placed to capitalise on the product


Deutsche Bank AG:

CENES PHARMACEUTICALS PLC (`the Company`)

HOLDING IN COMPANY

The Company was informed on 13 December 2004 that Deutsche Bank AG and its
subsidiary companies have an interest in 40,648,220 ordinary shares of 1p each
in the capital of the Company representing 9.92 per cent. of the issued share
capital of the Company.

Mehr Infos:

http://moneyextra.uk-wire.com/cgi-bin/index
search_type=3&words=cen" target="_blank" rel="nofollow ugc noopener">http://moneyextra.uk-wire.com/cgi-bin/index
search_type=3&words=cen

Gruss
B.M.

[BrauchGeld]

Hi


www.cenes.com

CENES PHARMACEUTICALS PLC (`the Company`)
HOLDING IN COMPANY

The Company was informed on 2 February 2005 that Deutsche Bank AG and its
subsidiary companies have an interest in 36,648,220 ordinary shares of 1p each
in the capital of the Company representing 8.95 per cent. of the issued share
capital of the Company.


Gruss
B.M.

[BrauchGeld]

Hi

MAJOR SHAREHOLDERS

Notifier Holding

Alan G Goodman 14,743,866

D J W Roach 12,224,789

Ron Irwin 344,333

Neil Clark 314,968

Peter Johnson 133,333



Cambridge, UK, 21st January 2005 - CeNeS Pharmaceuticals plc (LSE: CEN) (`CeNeS`
or `the Company`) today announced that further to the preliminary results
released on September 20th 2004 CeNeS now has the final audited results from a
European Phase III trial to assess the efficacy of M6G (morphine-6-glucuronide)
as an analgesic in patients suffering from post-operative pain. CeNeS is now
completing its plans for a final European Phase III trial. The trial is
anticipated to commence in the second quarter of 2005 . If this trial is also
successful CeNeS expects that it will be able to make a European product filing
in 2006 prior to a product launch in 2007.

Neil Clark, Chief Executive said `The global market for post-operative pain relief was valued at approximately $1 billion in 2000 , and is estimated to be
growing at 6-7% per annum.

[BrauchGeld]

Hi

Cenes wird von Nomura zum kauf empfohlen mit kurzziel 22p aktuell 8,38p.Wenn die Daten zu M6G im 2Q 2005 positiv ausfallen wird die aktie abgehen .

Gruss
B.M.

[BrauchGeld]

Hallo

CeNeS Pharmaceuticals PLC
11 April 2005

CeNeS announces additional clinical data supporting the potential of M6G for the
treatment of post-operative pain

Cambridge, UK, 11 April 2005 - CeNeS Pharmaceuticals plc (AIM: CEN) (`CeNeS` or
`the Company`) notes the recent publication of additional clinical data on its
lead product morphine-6-glucuronide (M6G) by an academic group at King`s
College, London. The data, which was published in the international journal
`Anesthesiology` (1), provides further support for the potential of M6G as a
treatment for post-operative pain, focusing on its potential for administration
under patient-controlled analgesia (PCA). Part of this data has been presented
previously at the 4th International Symposium for Nociceptive/Neuropathic Pain,
King`s College Hospital.

The study, which was a randomised, double-blind study comparing the analgesic
efficacy of M6G and morphine administered by initial bolus followed by PCA in
100 patients undergoing major joint replacement. Under the PCA system, patients
administer their own pain relief as and when it is needed.

The key findings of the study are:

•M6G has analgesic potency similar to that of morphine. The authors
speculate that the less effective pain control observed at early time points
in this study in patients on M6G could be due to the need for a large
loading dose or the product`s slower onset of action.
•There were clear differences between the M6G and morphine groups in terms
of respiratory depression rates. The proportion of subjects with respiratory
depression was markedly higher in the morphine group (27%) compared with the
M6G group (6%).
•There was significantly less sedation in the M6G group in the immediate
post-operative period as well as at the end of the 24 hour study period
•24 hours post-surgery, when the nausea rate was at its highest, 41% of
patients receiving morphine experienced nausea compared with 21% of those
receiving M6G. However, this difference did not reach the level of
statistical significance.
•The group concludes `it (M6G) has a unique pharmacodynamic profile with a
better therapeutic window than morphine. Its simple, clean pharmacokinetic
characteristics make it an attractive agent for further investigation...`


Commenting on the publication, Neil Clark, Chief Executive Officer of CeNeS
said, `This new data adds further support to our reported clinical trial results
and our belief in the potential of M6G as a new drug for the treatment of
post-operative pain with significant advantages over morphine and other opiates.
We believe that the less effective pain control observed with M6G at early time
points in this study is due to the low loading doses used. Our first Phase III
trial clearly showed that a higher loading dose of 30mg provides effective
analgesia. This higher loading dose regime will be used in our second Phase III
trial, which is expected to start in the next few months. If we are successful
in demonstrating the efficacy and superior side effect profile of M6G compared
to morphine in this large Phase III trial, which will involve approximately 440
patients, then we will have made a significant step towards the approval of the
product in Europe.`

(1) Randomized, Double-blind Study of the Analgesic Efficacy of
Morphine-6-Glucuronide versus Morphine Sulfate for Postoperative Pain in Major
Surgery. Anesthesiology V 102, No 4, April 2005, pp 815-821

[BrauchGeld]

Hi

CeNeS Pharmaceuticals PLC
20 April 2005


CeNeS Pharmaceuticals plc (`the Company`)

Holding in Company

The Company announces that it has received notification from Mr R G Robb esq.
that he has a notifiable interest in 15,000,000 Ordinary Shares of 1p each in
the Company, representing approximately 3.7% of the issued Ordinary Share
capital. These shares are registered in the name Hanover Nominees Limited.

[BrauchGeld]

Hi

Es werden wieder aktien von Cenes gekauft ein gutes zeichen.

Aktueller Kurs:9,63p +6,9%

CeNeS Pharmaceuticals plc ("the Company")

Director`s shareholding

The Company was today informed that on 28 April 2005 Mr Alan Goodman, Chairman
of the Company, purchased 100,000 ordinary shares of 1p each in the Company at a
price of 8.6 pence per share.

Following this purchase Mr Goodman has a beneficial interest in 14,843,866
ordinary shares representing 3.6% of the Company`s total issued share capital


CeNeS Pharmaceuticals plc (`the Company`)
Holding in Company

The Company announces that on 29 April 2005 it received notification from Mr R G
Robb Esq. that he has a notifiable interest in 16,500,000 Ordinary Shares of 1p
each in the Company, representing approximately 4.0% of the Company`s issued
ordinary share capital. This shareholding is registered in the name Hanover
Nominees Limited.

[BrauchGeld]

zu #4

Korrektur: Die daten zu CNS-5161 werden im 2Q bekannt gegeben und nicht die von M6G.

[BrauchGeld]

Hier sind noch ein paar Produkte an denen Cenes beteiligt ist.


http://www.cenes.com

Portfolio of carried interests
CeNeS holds a diverse range of carried interests with European and North American biotechnology companies following the divestment of non-core assets. In the longer-term, this portfolio could generate significant revenues to CeNeS if various milestones and targets are achieved under the agreed contracts. CeNeS continues to monitor the progress of these interests.



Asset
New owner / partner
CeNeS carried interest*

GGF2 - potential treatment for multiple sclerosis
Acorda Therapeutics, Inc
Milestones and royalties

CEE 03 310 - potential treatment for sleep disorders and substance abuse
Addex Pharmaceuticals SA
Milestones and royalties

Cognitive testing division
Cambridge Cognition Limited
Stage payments and milestone payments

Ion channel library
Scion Pharmaceuticals Inc
Stage payments and milestones

AutoPatch technology and certain ion channel assets
Xention Discovery Limited
Minority shareholding, loan note and certain rights over potential pain drug candidates arising from Xention`s work

[BrauchGeld]

Deutsche Bank kauft weiter aktien von Cenes.

CeNeS Pharmaceuticals PLC
06 May 2005



CENES PHARMACEUTICALS PLC (`the Company`)

HOLDING IN COMPANY


The Company was informed on 4 May 2005 that Deutsche Bank AG and its subsidiary
companies have an interest in 30,898,220 ordinary shares of 1p each in the
capital of the Company representing 7.54 per cent. of the issued share capital
of the Company.

[BrauchGeld]

Hi

Endlich ist die 10p marke nach über 8 mon.gefallen sieht auch charttechn. gut aus.
Hier ist noch viel luft nach oben.

Kurs:10,15p

[BrauchGeld]

Hi

CeNeS Pharmaceuticals PLC
13 May 2005


CENES PHARMACEUTICALS PLC (`the Company`)
HOLDING IN COMPANY


The Company was informed on 11 May 2005 that as at the close of business on 10
May 2005 The Goldman Sachs Group, Inc. (`GS Inc.`) had an interest, by
attribution only, in 26,762,626 ordinary shares of 1p each in the capital of the
Company. This interest arose from a beneficial interest held by Goldman Sachs
International, a wholly-owned indirect subsidiary of GS Inc. This shareholding
represents 6.53 per cent. of the issued share capital of the Company.


Schöne Feiertage

[BrauchGeld]

Presentation von April 05:
http://www.cenes.com/FinancialReports/CeNeS_Presentation.pdf

[BrauchGeld]

CeNeS Pharmaceuticals PLC
1 June 2005


New data on CeNeS compounds highlight the potential of its CNS pipeline


Cambridge, UK, 1st June 2005 - CeNeS Pharmaceuticals plc (AIM: CEN) (`CeNeS` or
`the Company`) today announced that recent presentations at two anaesthesia
congresses included new data on two of its product programmes:
morphine-6-glucuronide (M6G) for post-operative pain and CeNeS` short-acting
sedative programme.

In a talk at the European Society for Intravenous Anaesthesia (EuroSIVA, Vienna,
Austria 27th-28th May 2005 -
www.eurosiva.org
) entitled `New Drugs for Hypnosis
and Sedation` CeNeS` Director of Drug Discovery, Dr Gavin Kilpatrick, gave the
first public presentation of data on CeNeS` novel short-acting sedatives. The
data supports the desired profile of a rapid onset and rapid offset of action
and organ-independent metabolism. These compounds are being developed for use as
sedatives for patients undergoing short diagnostic and surgical procedures.
CeNeS` lead short-acting sedative compound, CNS 7056X, is in pre-clinical
development.

Immediately after the EuroSIVA meeting, the European Society for Anaesthesiology
meeting (ESA, Vienna, Austria 28th-31st May 2005 -
www.euroanesthesia.org
)
included a symposium on morphine metabolites at which the distinguished
academics, Professor Albert Dahan (Leiden, The Netherlands), Dr Magdi Hanna
(London, UK) and Professor Lona Christrup (Copenhagen, Denmark) presented data
on M6G.

The M6G presentations included new data from Professor Christrup`s unit at the
Danish University of Pharmaceutical Services on the oral bioavailability of M6G
and its potential use in the treatment of chronic pain. The conclusions
presented by Professor Christrup were:

1. The constant and prolonged absorption of M6G after peroral administration
might represent a physiological sustained release system, useful for the
treatment of chronic pain.


2. Due to its hydrophilic properties and consequently the slow rate of entering
into the CNS, M6G might have a low abuse potential compared to more
lipophilic opioids.


3. The prolonged duration of analgesia, which is probably due to accumulation
in brain extracellular fluid, makes M6G suited for treatment of chronic pain
conditions.


4. M6G appears to give rise to lesser nausea/vomiting and respiratory
depression than morphine.


5. Thus M6G might prove to be a therapeutic milestone in the treatment of
chronic pain.


The symposium also discussed previously released data on the use of M6G as an
analgesic for the treatment of post-operative pain and its reduced tendency to
cause respiratory depression compared to morphine. Overall, the feedback from
the attending anaesthetists was very positive regarding the potential clinical
profile of M6G.

CeNeS is developing M6G as a new treatment for post-operative pain and continues
to review M6G`s additional potential for the treatment of the chronic pain
market. The compound is in Phase III clinical trials in post-operative pain.

Neil Clark, Chief Executive commented:
`These are two of the most prestigious annual events for anaesthetists in
Europe. We are delighted to see that our programmes have achieved such a high
profile and that M6G continues to gain support as a potentially significant new
pain product.`

[BrauchGeld]

Hallo

Cenes präsentiert positive Daten



CeNeS Pharmaceuticals PLC
08 June 2005


CeNeS announces successful results from its Phase IIa clinical trial of CNS 5161
in neuropathic pain


Cambridge, UK, 8th June 2005 - CeNeS Pharmaceuticals plc (AIM: CEN) (`CeNeS` or
`the Company`) today announced successful results from its Phase IIa proof of
concept study of CNS 5161, its potent and selective NMDA antagonist, in
neuropathic pain. In the study, which was designed to establish the therapeutic
window of CNS 5161, the product was associated with a clear trend to improvement
in pain levels and was well tolerated with no instances of the psychotomimetic
side effects associated with some NMDA antagonists.

The Phase IIa study was a 48-patient, European multi-centre, double blind,
cross-over, dose escalating, preliminary safety and efficacy study, comparing a
single dose of CNS 5161 to placebo in order to establish a maximum tolerated
dose of CNS 5161. Intractable chronic neuropathic pain patients of varied
aetiology (such as diabetic neuropathy and post-traumatic neuropathy) were
investigated in the study. Four escalating dose levels (125, 250, 500 and 750
ug) of CNS 5161 were planned to be administered by intravenous infusion over six
hours, with study continuation to each higher dose subject to a satisfactory
safety review after each cohort of 12 patients had been completed. Recruitment
to the final cohort (750ug) was not completed due to hypertensive events (high
blood pressure), an expected outcome at higher doses. There were no
psychotomimetic side effects with CNS 5161, an important finding as such events
have been associated with some NMDA antagonists, causing them to be dropped from
development. This latter finding confirms CeNeS understanding that CNS 5161
occupies a unique position in its class.

In terms of pain relief, the study showed that 500ug of CNS 5161 was associated
with a clear trend to improvements in pain levels (measured using a Visual
Analogue Scale (VAS) ) at two, six and twelve hours after the start of the
intravenous infusion, when compared to placebo. The results were not
statistically significant as may be expected with small group sizes (12 patients
per dose group) in a proof of concept study. The analgesic effects of CNS 5161,
however, appeared to be demonstrated predominantly in the group of patients with
diabetic neuropathy. Further analysis of the data will be carried out to
investigate the apparent selectivity of CNS 5161 activity to the diabetic
neuropathy group. Compared to placebo, the lowest dose of 125ug showed no effect
on pain scores whilst the 250ug dose showed an improvement in pain scores that
was most evident at 24 hours. This latter observation supports previous clinical
findings with this compound. At all dose levels, CNS 5161 was well tolerated and
demonstrated a safety profile similar to that observed in earlier clinical
studies.

Neil Clark, CEO of CeNeS, said `CeNeS is very pleased that this proof of concept
dose escalating study has successfully established a therapeutic window for the
use of CNS 5161 as a potential treatment for neuropathic pain - a serious
chronic condition which is poorly treated at present. CeNeS will continue to
analyse the data from this and previous studies in order to plan the next steps
in the clinical development of this compound.`

[BrauchGeld]

Hallo

Auch wenn sich Cenes kaum vom fleck bewegt ist die aktie immer noch sehr aussichtsreich.
Nächstes jahr schon wird NDA beantragt so das anfang 2007 produkt M6G auf den Markt kommt .

Chairman Goodman kauft weitere 500.000 aktien.

CeNeS Pharmaceuticals PLC
30 June 2005


CeNeS Pharmaceuticals plc (`the Company`)

Director`s shareholding

The Company was informed today that Mr Alan Goodman, Chairman of the Company,
purchased 500,000 ordinary shares of 1p each in the Company at a price of
7.875 pence per share.

Following this purchase Mr Goodman has a beneficial interest in 15,343,866
ordinary shares representing 3.7% of the Company`s total issued share capital.

[BrauchGeld]

CeNeS Pharmaceuticals PLC
06 July 2005


CENES PHARMACEUTICALS PLC (`the Company`)

HOLDING IN COMPANY


The Company was informed on 4 July 2005 that as at the close of business on 4
July 2005 The Goldman Sachs Group, Inc. (`GS Inc.`) had an interest, by
attribution only, in 29,752,626 ordinary shares of 1p each in the capital of the
Company. This interest arose from a beneficial interest held by Goldman Sachs
International, a wholly-owned indirect subsidiary of GS Inc. This shareholding
represents 7.3 per cent. of the issued share capital of the Company.

-----------


CeNeS Pharmaceuticals plc: Annual General Meeting (AGM) statement

Cambridge, UK, 5 July 2005 -CeNeS announces that all resolutions put to
Shareholders at today`s AGM were passed.

At the AGM CeNeS` Chairman Alan Goodman said: `In the last nine months CeNeS
has delivered two successful clinical trial results, the first being a Phase
III trial of our lead programme M6G for post-operative pain, that demonstrated
its efficacy as an analgesic. The second successful result was in a Phase II
proof of concept study of CNS 5161 in neuropathic pain. These results are
evidence of the expertise of our clinical development team and their ability to
design and implement clinical programmes. We look forward with confidence to
progressing both these compounds to the next stages of their clinical
development and also moving CNS 7056X, our novel short acting sedative, into
the clinic in 2006.

Our earlier stage programme developing novel COMT (catechol-o-methyl
transferase) inhibitors is also progressing well. The market for COMT
inhibitors may expand substantially as the role of COMT is better understood in
schizophrenia and other cognitive disorders in addition to the established
market for the treatment of Parkinson`s disease.

I firmly believe CeNeS is well positioned to deliver value to its shareholders
by further developing its balanced portfolio focused on improved treatments for
disorders of the central nervous system and pain. CeNeS is looking forward with
confidence to reaching important milestones in each of its programmes in the
next 12 to 18 months.`

-------------------